Vicore’s C21 reduces long-term lung injury after COVID-19 in the ATTRACT Phase 2 extension study
- Tuesday, November 2, 2021, 2:17
- Finance
- Add a comment
GOTHENBURG, Sweden, Nov. 2, 2021 /PRNewswire/ — Vicore Pharma Holding AB (publ) (“Vicore”), a rare disease pharmaceutical company developing innovative medicines for severe lung disorders today announces results that treatment with the company’s AT2R agonist C21 reduces long-term lung…
About the Author
adminasapcorp has written 39051 stories on this site.